Analysts Set Expectations for TSHA FY2026 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Taysha Gene Therapies in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.42) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.

Several other analysts also recently weighed in on TSHA. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. JMP Securities increased their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a report on Thursday, May 29th. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Canaccord Genuity Group lifted their price objective on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd. Finally, Chardan Capital raised their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $7.57.

Taysha Gene Therapies Stock Down 0.7%

Shares of TSHA traded down $0.02 during midday trading on Wednesday, reaching $2.65. The stock had a trading volume of 4,230,552 shares, compared to its average volume of 3,085,864. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $4.32. The company has a market cap of $568.85 million, a price-to-earnings ratio of 4.21 and a beta of 1.04. The company's fifty day simple moving average is $2.15 and its two-hundred day simple moving average is $1.94.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same quarter in the prior year, the company earned ($0.10) earnings per share.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, major shareholder Paul B. Manning bought 750,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the purchase, the insider now owns 2,841,704 shares in the company, valued at approximately $7,814,686. The trade was a 35.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently modified their holdings of TSHA. Quantum Private Wealth LLC boosted its stake in shares of Taysha Gene Therapies by 3.6% in the fourth quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company's stock valued at $1,375,000 after purchasing an additional 27,360 shares during the period. Bank of New York Mellon Corp lifted its stake in Taysha Gene Therapies by 33.1% during the fourth quarter. Bank of New York Mellon Corp now owns 450,261 shares of the company's stock worth $779,000 after purchasing an additional 111,989 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Taysha Gene Therapies by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after buying an additional 11,390 shares during the period. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $31,000. Finally, Commonwealth Equity Services LLC lifted its stake in Taysha Gene Therapies by 110.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company's stock valued at $102,000 after buying an additional 31,000 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.